PhaseBio Obtains $34M in Financing to Advance Therapies for PAH, Other Diseases
News, PAH News
PhaseBio Pharmaceuticals has secured $34 million in Series D financing to advance the clinical development of PB1046, an investigational therapy for pulmonary arterial hypertension (PAH), as well as its lead ... Read more